Tenderwize
Zurück zur Suche

Open house drug discount agreements for active substance Interferon beta-1b, ATC L03AB08

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 217 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Interferon beta-1b, ATC L03AB08

60/100

Opportunity Score

PromisingLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

60 / 100

Komplexität

30 / 100

Risikofaktoren

Open house contracts can be replaced by exclusive contracts at any time, leading to automatic termination.

Initial submission deadline (April 30, 2025) is only 19 days after notice publication (April 11, 2025).

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Strong opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of non-exclusive discount agreements for Interferon beta-1b under open-house model
  • Contracts available to all interested pharmaceutical companies
Vollständige Zusammenfassung anzeigen

Non-exclusive discount agreement ('Rabattvertrag') for the active substance Interferon beta-1b (ATC L03AB08) under an open-house model. All interested pharmaceutical companies meeting eligibility can join. Contracts run up to 24 months from June 1, 2025. Initial submission deadline for first contracts: April 30, 2025. No estimated value provided. The notice explicitly states it is not a public procurement under EU law; published for transparency only.

Risiken

Open house contracts can be replaced by exclusive contracts at any time, leading to automatic termination.

Initial submission deadline (April 30, 2025) is only 19 days after notice publication (April 11, 2025).

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Proof of marketability via Lauer-Taxe listing or AMIce database extract

Eligibility

  • Only authorized and marketable medicines in Germany are eligible

Administrative

  • Submission of signed contract documents by specified deadlines

Anforderungen können unvollständig sein.

Auftraggeber

Lose (1)

LOT-0001

Open house drug discount agreements for active substance Interferon beta-1b, ATC L03AB08

Conclusion of non-exclusive discount agreements for Interferon beta-1b under open-house model. All pharmaceutical companies can join under uniform conditions. Contracts are non-exclusive and may be replaced by exclusive agreements later. Maximum contract duration 24 months.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

May 2025 - May 2027

Kategorie

Pharmaceutical products

Vergabedetails

Veröffentlichungsdatum
10 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
235668-2025

Dokumente (1)

Ähnliche Ausschreibungen